Androgenic Agents, Topical  
Therapeutic Class Review (TCR)  

March 1, 2017

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management.

All requests for permission should be mailed to:

Magellan Rx Management  
Attention: Legal Department  
6950 Columbia Gateway Drive  
Columbia, Maryland 21046

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCREditor@magellanhealth.com.
FDA-APPROVED INDICATIONS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Manufacturer</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>testosterone gel (AndroGel®)¹,²</td>
<td>generic, AbbVie</td>
<td>Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, such as primary or secondary hypogonadism (congenital or acquired)*</td>
</tr>
<tr>
<td>testosterone gel (Fortesta®)³</td>
<td>generic, Endo</td>
<td></td>
</tr>
<tr>
<td>testosterone gel (Testim®)⁴</td>
<td>generic, Auxilium</td>
<td></td>
</tr>
<tr>
<td>testosterone gel (Vogelxo®)⁵</td>
<td>generic, Upsher-Smith</td>
<td></td>
</tr>
<tr>
<td>testosterone nasal gel (Natesto™)⁶</td>
<td>Endo</td>
<td></td>
</tr>
<tr>
<td>testosterone solution (Axiron®)⁷</td>
<td>Lilly</td>
<td></td>
</tr>
<tr>
<td>testosterone transdermal system (Androderm®)⁸</td>
<td>Actavis</td>
<td></td>
</tr>
</tbody>
</table>

* Safety and efficacy in men with “age-related hypogonadism” or in males less than 18 years old have not been established. Topical testosterone products have different doses, strengths, or application instructions that may result in different systemic exposure.

OVERVIEW

Male hypogonadism is caused by insufficient production of testosterone and characterized by low serum concentrations. Hypogonadism may present as testosterone deficiency, infertility, or both. Symptoms at presentation will primarily depend on the patient’s age at the time of disease onset and can include impotence, decreased libido, fatigue, loss of energy, mood depression, and regression of secondary sex characteristics. Potential risks due to male hypogonadism include osteoporosis, sexual dysfunction, depression, and cardiovascular disease. Approximately 20% of men ages 60 to 69 years old and 30% of men ages 70 to 79 years old have serum testosterone levels below the normal range.

Causes of hypogonadism are classified as primary, due to failure of the testes, or secondary, due to failure of the hypothalamus or pituitary gland. Either type of hypogonadism, may be caused by an inherited (congenital) or acquired factor. Conditions resulting in primary male include hypogonadism include cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, chemotherapy, radiation therapy, toxic damage from alcohol or heavy metals, testicular infections (such as mumps) and chromosomal abnormalities such as Klinefelter’s Syndrome. Patients usually present with low testosterone levels and elevated follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels. Secondary (hypogonadotrophic) hypogonadism includes idiopathic gonadotropin or luteinizing hormone releasing hormone (LHRH) deficiency and pituitary hypothalamic injury from tumors, trauma, or radiation. Testosterone levels are low in patients with secondary hypogonadism, but FSH and LH levels are low or in the normal range.

Testosterone levels are associated with a diurnal rhythm; the highest levels occur during the early morning hours. The testes produce 6 to 7 mg of testosterone daily, resulting in normal circulating testosterone levels ranging from 300 to 1,000 ng/dL. Testosterone supplementation can maintain
secondary sex characteristics, optimize bone density, and restore fertility. Oral administration of testosterone is ineffective due to first-pass metabolism in the liver, so injectable and transdermal methods of delivery are ideal. Transdermal delivery of testosterone is appealing to some patients as it is convenient to use and eliminates frequent office visits often required by injectable testosterone.

The 2002 treatment guidelines for hypogonadism published by the American Association of Clinical Endocrinologists (AACE) do not list a preferred method of delivery for testosterone replacement. The 2010 Endocrine Society treatment guidelines for androgen deficiency syndromes recommend testosterone therapy for symptomatic men with classical androgen deficiency syndromes aimed at inducing and maintaining secondary sex characteristics and at improving their sexual function, sense of well-being, and bone mineral density. The guidelines suggest initiating testosterone therapy using testosterone patches or gel, bioadhesive buccal tablets, injectable testosterone enanthate or cypionate or implanted pellets chosen on the basis of the patient’s preference, consideration of pharmacokinetics, treatment burden, and cost. The guidelines cite frequent skin reactions at application site as a potential adverse event for testosterone patch formulations. They cite skin irritation and testosterone transfer to another person who is in close contact as a potential adverse event for the transdermal gel formulations. The guidelines recommend against testosterone therapy in patients with breast or prostate cancer. They recommend against testosterone therapy without further urological evaluation in patients with palpable prostate nodule or induration or prostate specific antigen (PSA) 4 ng/mL or PSA 3 ng/mL in men at high risk of prostate cancer, such as African Americans or men with first-degree relatives with prostate cancer. The guidelines also recommend against testosterone treatment in patients with hematocrit greater than 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms associated with benign prostatic hypertrophy, and uncontrolled or poorly controlled congestive heart failure.

Treatment goals are continuation of normal activities of daily living and decreased risk of secondary complications such as infertility, osteoporosis, fatigue, and mood disturbances.

**PHARMACOLOGY**

Topical androgens deliver physiologic amounts of testosterone to the patient, producing testosterone levels correlating with concentrations seen in healthy men. Testosterone is bound in the serum to sex hormone-binding globulin (SHBG) and albumin. Approximately 40% of testosterone in plasma is bound to SHBG and is not biologically active. In addition, SHBG production increases with age, so increasing amounts of testosterone will be bound as men age. Two percent of testosterone is unbound, and the remainder is bound to albumin. The portion bound to albumin is considered to be biologically active since it freely dissociates from albumin.

In many tissues, the activity of testosterone depends on the conversion to dihydrotestosterone (DHT). DHT binds to cytosol receptor proteins; this complex initiates androgenic actions in cell nuclei. DHT is further metabolized to 3α- and 3β-androstanediol.
PHARMACOKINETICS\textsuperscript{21,22,23,24,25,26,27,28}

<table>
<thead>
<tr>
<th>Drug</th>
<th>( T_{\text{max}} ) (hours)</th>
<th>( C_{\text{avg}} ) (ng/dL)</th>
<th>( T_{1/2} ) (minutes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>testosterone gel (AndroGel 1%)</td>
<td>2</td>
<td>566–792</td>
<td>10–100</td>
</tr>
<tr>
<td>testosterone gel (AndroGel 1.62%)</td>
<td>8</td>
<td>386–643</td>
<td>10–100</td>
</tr>
<tr>
<td>testosterone gel (Fortesta)</td>
<td>4</td>
<td>415–964*</td>
<td>10–100</td>
</tr>
<tr>
<td>testosterone gel (Testim)</td>
<td>4–8</td>
<td>365–612</td>
<td>10–100</td>
</tr>
<tr>
<td>testosterone gel (Vogelxo)</td>
<td>4–8</td>
<td>365–612</td>
<td>10–100</td>
</tr>
<tr>
<td>testosterone nasal gel (Natesto)</td>
<td>0.66</td>
<td>305–537</td>
<td>10–100</td>
</tr>
<tr>
<td>testosterone solution (Axiron)</td>
<td>2</td>
<td>456–480</td>
<td>10–100</td>
</tr>
<tr>
<td>testosterone transdermal (Androderm)</td>
<td>4–12</td>
<td>300–1,030</td>
<td>10–100</td>
</tr>
</tbody>
</table>

*Reported for 40 to 70 mg doses

Bioavailability of each product is variable, but most report absorption rates of approximately 10%. One small study found testosterone gel preparations (AndroGel, Testim) were not bioequivalent; Testim provided higher serum levels than AndroGel when equivalent dosing was used.\textsuperscript{29} Vogelxo is considered AB-rated (therapeutically equivalent) to Testim gel.\textsuperscript{30}

Information regarding the excretion of testosterone is only available for intramuscular administration. By this route, 90\% of a dose is excreted in the urine as metabolites, and 6\% appears unchanged in the feces.

CONTRAINDICATIONS/WARNINGS\textsuperscript{31,32,33,34,35,36,37,38}

The entire gel and solution products listed (AndroGel, Axiron, Fortesta, Testim, and Vogelxo) carry a boxed warning on virilization of children following secondary exposure. The boxed warning does not presently include testosterone patches or testosterone nasal gel, although women and children are cautioned to avoid exposure.

Use of testosterone products is contraindicated in men with carcinoma of the breast or known prostate carcinoma. Testosterone products are Pregnancy Category X and should not be used or handled by women who are pregnant, may become pregnant, or are breastfeeding.

In May 2009, FDA issued a safety alert for testosterone gel products, AndroGel and Testim, due to 8 reports of children experiencing adverse effects after unintended exposure to testosterone through contact with an individual being treated with these agents.\textsuperscript{39} Virilization has been reported in children who were secondarily exposed to testosterone gel. All of the manufacturers of the testosterone gel and solution products are required to include a boxed warning in the medications’ labels related to this safety issue.
Prolonged use of high doses of orally active 17-alkyl androgens such as methyltestosterone has been associated with severe hepatic adverse effects. Testosterone is not known to cause these effects.

Patients diagnosed with benign prostatic hyperplasia (BPH) and treated with androgens are at an increased risk for worsening of signs and symptoms of the disease. Additionally, patients treated with androgenic agents are at increased risk for developing prostatic carcinoma. Surveillance for prostate cancer is also recommended in this population as well as other patients with risk factors.

Sleep apnea, gynecomastia, and edema with or without congestive heart failure are also possible.

All topical testosterone products should be applied according to the specific administration instructions contained in the application instructions. Products should be applied evenly and not to areas not specified for each product, such as genitals, abdomen, behind the knees, or other locations.

Laboratory values requiring periodic monitoring during testosterone therapy include hemoglobin/hematocrit, liver function, prostate specific antigen, cholesterol, high-density lipoprotein cholesterol (HDL-C), and serum calcium.

All testosterone products are Schedule III controlled substances.

The FDA has issued a warning that prescription testosterone products are approved only for men who have low testosterone levels caused by certain medical conditions. The benefit and safety of these medications have not been established for the treatment of low testosterone levels due to aging, even if a man’s symptoms seem related to low testosterone. The FDA has also concluded that there is a possible increased cardiovascular risk associated with testosterone use. This is based on 2 recent studies that suggest an increased risk of cardiovascular events among men prescribed testosterone therapy. Manufacturers are required to clarify the approved uses of these medications and add information to the labeling about a possible increased risk of myocardial infarctions and strokes in patients taking testosterone. In response, AACE/American College of Endocrinology (ACE) issued a position statement stating that the benefits of testosterone replacement in patients with low testosterone outweigh the risks. They further noted that the correlation of cardiovascular risk may be due to low testosterone serving as a marker of cardiovascular disease rather than testosterone supplementation as a causative factor and stated that larger, prospective studies are needed to determine the cardiovascular benefits and risks associated with testosterone therapy.

Androderm, AndroGel 1%, AndroGel 1.62%, Axiron, Natesto, Fortesta, Testim, and Vogelxo all carry an updated warning citing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products. Patients who report or exhibit symptoms of pain, edema, warmth, and erythema in the lower extremity should be evaluated for possible DVT, while those presenting with acute shortness of breath should be evaluated for potential PE. If there is evidence or suspicion of a possible venous thromboembolic event, topical testosterone therapy should be discontinued and appropriate venous thromboembolism (VTE) management initiated.

Androderm, AndroGel 1%, AndroGel 1.62%, Axiron, Natesto, Fortesta, Testim, and Vogelxo also now carry an updated warning regarding potential abuse of testosterone containing products and the possible need to monitor serum testosterone concentrations. Testosterone use has been well documented to be subject to abuse, especially when administered at higher doses than recommended for testosterone replacement therapy and when given in combination with other anabolic androgenic steroids. Such abuse may lead to serious cardiovascular and psychiatric adverse reactions. If testosterone abuse is suspected when using these medications, serum testosterone concentrations
should be checked and monitored to ensure they are within therapeutic range. Should the abuse involve synthetic testosterone derivatives, testosterone levels may still found to be in normal or subnormal ranges. In such cases, patients should be warned of the serious adverse reactions that may occur with abuse of testosterone and anabolic androgenic steroids. Conversely, testosterone and anabolic androgenic steroid abuse should be strongly considered in patients who suddenly present with serious cardiovascular or psychiatric adverse events.

Testosterone nasal gel (Natesto) is not recommended in patients with chronic nasal conditions or alterations in nasal anatomy. In addition, patients should report any signs or symptoms of nasal adverse effects.

Risk Evaluation and Mitigation Strategy (REMS)

At this time, all products in this review, except testosterone patches (Androderm) and testosterone nasal gel (Natesto), require medication guides as a component of REMS to be provided to patients using testosterone therapy.

**DRUG INTERACTIONS**

Testosterone can cause reductions in blood glucose levels. Patients being treated with testosterone and insulin simultaneously may have lower insulin requirements.

Changes in anticoagulant activity have also been observed in patients receiving both anticoagulant medications and testosterone therapy. It is recommended that patients with concurrent therapy have more frequent monitoring of their prothrombin time (PT) and International Normalized Ratio (INR).

When administered with corticosteroids, testosterone may increase the incidence and extent of edema. Cautious use is advised in patients with hepatic or cardiac disease.
ADVERSE EFFECTS50,51,52,53,54,55,56,57

<table>
<thead>
<tr>
<th>Drug</th>
<th>Application Site Reaction</th>
<th>Headache</th>
<th>Acne</th>
<th>Hypertension</th>
<th>Gynecomastia</th>
<th>Increased Hemoglobin/Hematocrit</th>
</tr>
</thead>
<tbody>
<tr>
<td>testosterone gel (Androgel 1%)</td>
<td>3–5.6</td>
<td>0–4</td>
<td>1–8</td>
<td>0–3</td>
<td>0–3</td>
<td>reported</td>
</tr>
<tr>
<td>testosterone gel (Androgel 1.62%)</td>
<td>2.1</td>
<td>nr</td>
<td>≤ 2</td>
<td>2.1</td>
<td>nr</td>
<td>2.1</td>
</tr>
<tr>
<td>testosterone gel (Fortesta)</td>
<td>16.1</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>testosterone gel (Testim)</td>
<td>2–4</td>
<td>1</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>0–1</td>
<td>1–2</td>
</tr>
<tr>
<td>testosterone gel (Vogelxo)</td>
<td>2–4</td>
<td>1</td>
<td>&gt; 1</td>
<td>1</td>
<td>0–1</td>
<td>1</td>
</tr>
<tr>
<td>testosterone nasal gel (Natesto)</td>
<td>nr</td>
<td>3</td>
<td>nr</td>
<td>2–3</td>
<td>nr</td>
<td>&lt; 2</td>
</tr>
<tr>
<td>testosterone solution (Axiron)</td>
<td>7–8</td>
<td>5–6</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>4–7</td>
</tr>
<tr>
<td>testosterone transdermal (Androderm)</td>
<td>17</td>
<td>&lt; 3</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
</tr>
</tbody>
</table>

Adverse effects are reported as a percentage. Adverse effects data are obtained from package inserts and are not meant to be comparative or all inclusive. nr = not reported.

Nasal adverse effects have been reported with testosterone nasal gel (Natesto). These nasal adverse effects include nasopharyngitis (8.2%), rhinorrhea (7.8%), epistaxis (6.5%), discomfort (5.9%), parosmia (5.2%), nasal scab (5.2%), upper respiratory infection (4.2%), dryness (4.2%), and congestion (3.9%).

SPECIAL POPULATIONS58,59,60,61,62,63,64,65

Pediatrics

Testosterone products have not been evaluated in pediatric patients. None of the agents within this class (Androderm, Androgel, Axiron, Fortesta, Testim, Natesto, and Vogelxo) are approved for use in patients less than 18 years of age. Exposure may result in acceleration of bone age and premature closure of epiphyses. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel products.

Pregnancy

The products in this review are Pregnancy Category X.

Geriatrics

Testosterone transdermal products have not included sufficient numbers of patients 65 years and older in controlled clinical studies to determine whether there is a difference in efficacy and safety from results
seen in younger patients. There are an insufficient number of long-term safety studies to assess whether there are variances in prostate cancer or cardiovascular risks between geriatric and younger patients.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosing</th>
<th>Administration</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>testosterone 1% gel (Androgel 1%)</td>
<td>5 g daily, preferably in the morning (delivers 5 mg systemically); Dosing may be increased to 10 mg (by 2.5 mg increments)</td>
<td>Apply to clean, dry, intact skin of the shoulders and upper arms; Do not apply to the genitals</td>
<td>2.5, 5 g packets (contains 25 mg or 50 mg testosterone, respectively; 30 packets); 75 g pump with 60 pump actuations delivering 12.5 mg of testosterone per actuation (1.25 g of gel)</td>
</tr>
<tr>
<td>testosterone 1.62% gel (Androgel 1.62%)</td>
<td>40.5 mg (1.25 g of gel) once daily; Dosing may be adjusted between 20.25 mg and 81 mg based on levels drawn at 14 and 28 days after start of therapy</td>
<td>Apply to clean, dry, intact skin of the shoulders and upper arms; Do not apply to the genitals</td>
<td>1.25, 2.5 g packets (contains 20.25 mg or 40.5 mg testosterone, respectively; 30 packets); 75 g pump with 60 pump actuations delivering 20.25 mg of testosterone per actuation (1.25 g of gel)</td>
</tr>
<tr>
<td>testosterone gel (Fortesta)</td>
<td>Initiate at 40 mg once every morning; Dosing may be adjusted from 10 mg to 70 mg based on levels 2 hours after application at days 14 and 35 after start of last adjustment</td>
<td>Apply to clean, dry, intact skin of the front and inner thighs; Do not apply to genitals or other parts of the body</td>
<td>In a 60 g canister with metered dose pump delivering 10 mg testosterone in 0.5 g gel per actuation</td>
</tr>
<tr>
<td>testosterone 1% gel (Testim)</td>
<td>5 g daily, preferably in the morning (delivers 5 mg systemically)</td>
<td>Apply to clean, dry, intact skin of the shoulders and/or upper arms; Do not apply to genitals or abdomen</td>
<td>5 g tubes (30 per package)</td>
</tr>
<tr>
<td>testosterone gel (Vogelxo)</td>
<td>50 mg applied topically once daily at approximately the same time each day; Dosing may be adjusted to 100 mg once daily based on levels drawn at 14 days after start of therapy; Maximum dose is 100 mg daily</td>
<td>Apply to clean, dry, intact skin of the shoulders and/or upper arms; Do not apply to genitals or abdomen</td>
<td>In unit-dose tubes or packets containing 50 mg testosterone in 5 g of gel; multiple-dose metered pumps delivering 12.5 mg of testosterone in 1.25 g of gel per actuation</td>
</tr>
<tr>
<td>testosterone nasal gel (Natesto)</td>
<td>11 mg total, or 1 pump actuation in each nostril, 3 times a day (once in the morning, once in the afternoon, and once in the evening, about 6 to 8 hours apart); Maximum total daily dose is 33 mg intranasally</td>
<td>Patients should blow nose prior to administration; Actuator should be tipped toward lateral wall of nostril to ensure gel is applied appropriately prior to pressing the pump; Refrain from blowing nose or sniffing for 1 hour following administration; Do not apply to genitals or abdomen</td>
<td>Metered dose pump containing 11 g of gel dispensed as 60 metered pump actuations; each actuation delivers 5.5 mg of testosterone</td>
</tr>
<tr>
<td>testosterone solution (Axiron)</td>
<td>Initiate at 60 mg once a day; Dosing may be adjusted 30 mg based on levels drawn 2 to 8 hours after application at days 14 after start or last adjustment</td>
<td>Apply to clean, dry, intact skin of the axilla preferably at the same time every morning; Do not apply to the genitals or other parts of the body</td>
<td>110 mL of topical solution in a metered dose pump; each pump delivers 30 mg of testosterone in 1.5 mL of solution; each bottle has an applicator top</td>
</tr>
</tbody>
</table>
**Dosages (continued)**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosing</th>
<th>Administration</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>testosterone transdermal (Androderm)</td>
<td>4 mg daily (nightly)</td>
<td>Apply to clean, dry skin of the back, abdomen, upper arms, or thighs; do not apply to genitals, bony prominences, or parts of the body that may be subject to prolonged pressure due to sitting or sleeping; rotate sites every 7 days</td>
<td>2 mg patches (60 per carton); 4 mg patches (30 per carton)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Patches contain 9.7 mg testosterone (delivering 2 mg/day) or 19.5 mg (delivering 4 mg/day)</td>
</tr>
</tbody>
</table>

The old Androderm strengths (2.5 mg/day and 5 mg/day patches) have been discontinued and are no longer available. AbbVie plans to discontinue Androgel 1% pump in the future. Androgel 1% packets and all Androgel 1.62% formulations will continue to be produced.

Prior to initiating therapy the diagnosis of hypogonadism should be confirmed by measuring serum testosterone concentrations in the morning on at least 2 separate days with the resulting concentrations being below the normal range.

Testosterone levels should be measured, typically 14 days following initiation of therapy to determine dosage adjustments.

The application sites and dosing recommendations among testosterone replacement products are not interchangeable. Label instructions must be strictly followed to ensure safety and efficacy in use of these products.

Wash hands after applying gels; allow administration area of the gel to dry for several minutes before dressing. Cover the application site once it is dry. Drug can be transferred to others through vigorous skin-to-skin contact. Should skin-to-skin contact with another person be anticipated, the application site should be washed prior to such contact.

Alcohol based products, including Androgel, Axiron, Fortesta, Testim, and Vogelxo are flammable. Patients should be advised to avoid smoking, fire or flame until the dose applied has dried.

Do not swim or shower within 2 hours after application of Androgel 1.62%, Axiron, Testim, or Vogelxo and 5 hours after application of Androgel 1% to achieve maximum benefit. Do not swim, shower, or wash the site of administration for Androderm transdermal testosterone for 3 hours following application.

The dosing and administration for Androgel 1% and Androgel 1.62% are not equivalent. Refer to the prescribing information and the table above for the correct dosing of each product.

The occlusive backing of Androderm prevents sexual partners from coming into contact with active drug. Mild skin irritation with Androderm can be lessened by applying over-the-counter hydrocortisone cream following removal of the patch. Alternately, triamcinolone 0.1% cream may be applied to the skin beneath the drug reservoir of the patch. Use of ointments for this purpose may decrease testosterone absorption.

**CLINICAL TRIALS**

**Search Strategies**

Studies were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all drugs in this class. Studies included
for analysis in the review were published in English, performed with human participants and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question and include follow-up (endpoint assessment) of at least 80% of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship/funding must be considered, the studies in this review have also been evaluated for validity and importance. Many of the trials with agents in this class were performed in an open-label manner; introduction of bias must be considered when evaluating study findings.

The method of administration and associated monitoring makes it difficult to perform properly blinded studies with these drugs. Due to the lack of double-blind studies, open-label studies have been included; while these studies may produce accurate results, the study design should be taken into consideration.

testosterone gel (Fortesta)

Testosterone gel (Fortesta) was evaluated in a multicenter, 90-day open-label, non-comparative trial of 149 hypogonadal male subjects with body mass index (BMI) \( \geq 22 \, \text{kg/m}^2 \) and \(< 35 \, \text{kg/m}^2 \) and 18 to 75 years of age (mean 54.5 years).\(^{74}\) Patients were screened for a single serum total testosterone concentration of \(< 250 \, \text{ng/dL} \) or 2 consecutive serum concentrations \(< 300 \, \text{ng/dL} \). A dose of 40 mg was applied daily to the thighs, with adjustments between 10 mg and 70 mg of testosterone based on serum testosterone levels taken 2 hours after application taken on days 14, 35, and 60. The primary endpoint was the percentage of subjects with a normal testosterone concentration, defined as \( \geq 300 \) to \( \leq 1140 \, \text{ng/dL} \), at day 90. At day 90, 77.5% of patients had achieved a normal testosterone concentration, and no patient had a maximum testosterone concentration \( \geq 2,500 \, \text{ng/dL} \) on day 90.

testosterone gel (Axiron)

Testosterone gel (Axiron) was evaluated in a multicenter, open label, 120-day trial across 26 centers and including 155 hypogonadal male subjects.\(^{75}\) The median age for all subjects was 53 years with an age range from 19 to 78 years. Patients were instructed to apply testosterone gel according to the prescribed manner and not to alter current grooming habits. Patients received an Axiron dose of 60 mg during the initial treatment stage on days 1 through 15, and 76.1% of patients achieved an average serum total testosterone level in the normal range, defined as 300 to 1,050 ng/dL. On day 45, doses were adjusted based on their average serum testosterone level, as measured on day 15. Dose adjustment occurred again on day 90, based on the testosterone level taken on day 60. On day 60, 84.8% of subjects had a normal average serum testosterone level. The study concluded on day 120, at which point 84.1% of patients experienced a normal average serum testosterone level.

testosterone gel (Vogelxo)

Testosterone gel (Vogelxo) was evaluated in a randomized, multicenter, multi-dose, active and placebo controlled 90-day trial involving 406 adult males with morning testosterone levels of \( \leq 300 \, \text{ng/dL} \).\(^{76}\) The study was double-blind for the doses of testosterone gel and placebo, but open-label for the non-scrotal testosterone transdermal system. During the first 60 days, patients were equally randomized to receive either testosterone gel 50 mg, testosterone gel 100 mg, placebo gel, or testosterone transdermal
system. At day 60 of the trial, patients receiving testosterone gel were either maintained at the same dose, or were titrated up or down within their treatment group, based on 24-hour averaged serum testosterone concentration levels previously obtained on day 30. Of 192 hypogonadal males in the trial who were appropriately titrated with testosterone gel and who had generated sufficient data for analysis, 74% achieved an average serum testosterone level within the normal range (300 to 1,000 ng/dL) by treatment day 90.

**testosterone nasal gel (Natesto)**

Testosterone nasal gel was studied in an open-label, multicenter, 90-day phase 3 trial in 306 hypogonadal men. Testosterone was administered intranasally either 2 or 3 times daily. During the treatment period (days 1 to 90), 78 patients were treated with 33 mg of testosterone daily. Of these, a total of 73 men were included in the statistical evaluation of efficacy on day 90 based on the intent-to-treat (ITT; n=73) population with last observation carried forward (LOCF). A total of 90% of these patients had an average serum testosterone concentration \(C_{avg}\) within the normal range [300 to 1,050 ng/dL] on day 90 (primary endpoint). The percentage of patients with \(C_{avg}\) below the normal range (< 300 ng/dL) on day 90 was 10% and no subject had a \(C_{avg}\) value exceeding 1,050 ng/dL.

**testosterone transdermal patch (Androderm)**

Testosterone transdermal (Androderm new formulation) was evaluated in a comparative trial to evaluate dosing and titration of the new 2 mg/day and 4 mg/day systems in 40 males with hypogonadism in a clinic setting. Mean age was 55 years (range 34 to 76 years). Patients had previously been stabilized on either Androderm 5 mg; Androgel 2.5 g, 5 g, 7.5 g, 10 g; or Testim 2.5 g or 5 g daily prior to the trial. Testosterone transdermal was applied nightly at 2,000 hours for 14 days. Dosing was titrated based on serum concentrations taken the morning of Day 8. Of patients formerly receiving Androderm 5 mg/day (n=11) 10 subjects remained at the 4 mg/day dosing and 1 was titrated down to the 2 mg/day dosing. At the 28-day mark, 97% of trial subjects had serum testosterone \(C_{avg}\) measurements within the normal range for the dosing period.

**testosterone gel (Androgel) and testosterone transdermal patch (Androderm)**

Effects of 180 days of treatment with testosterone 1% gel (50 or 100 mg/day) compared to testosterone patch (5 mg/day, old formulation) on defined efficacy parameters were studied in 227 hypogonadal men. The randomized, parallel group study was double-blinded with respect to gel dose and open-label for the patch group. In the gel groups, the dose was adjusted up or down to 75 mg/day on day 90 if serum testosterone concentrations were below or above the normal male range. No dose adjustment was made in the patch group. Sexual function and mood, as monitored by questionnaire, improved maximally on day 30 of treatment without differences across groups and were maintained for the duration of therapy. Mean muscle strength in the leg press exercise increased by 11 to 13 kg in all treatment groups by 90 days and did not improve further at the end of treatment. Moderate increases were also observed in arm/chest muscle strength. At 90 days of treatment, lean body mass increased more in the 100 mg/day gel group than in the 50 mg/day gel and patch groups (2.74 versus 1.28 versus 1.2 kg, \(p=0.0002\)). Beneficial effects were accompanied by anticipated increases in hematocrit and hemoglobin but without significant changes in lipid profile. Skin irritation was reported in 5.5% of subjects treated with gel and in 66% of subjects in the patch group.
testosterone gel (Testim) and testosterone transdermal patch (Androderm)

To compare the safety and efficacy of 2 doses of testosterone 1% gel (50 or 100 mg/day) and a testosterone patch (2 x 2.5 mg, old formulation), 208 men with confirmed low serum testosterone levels and associated signs and symptoms of hypogonadism were randomized and treated for 90 days. The study was double-blinded with respect to the gel dose and open-label for the patch group. Pharmacokinetic profiles were obtained, body composition measured, and mood and sexual function data recorded. Mean increases from baseline to 90 days in testosterone were 12.41, 6.54, and 3.82 nmol/L for the 100 and 50 mg gel groups and the patch (p<0.05), respectively. Both doses of gel significantly improved positive and negative mood over baseline; the patch did not (p<0.05). All 3 treatments increased lean body mass. At all sample times, both doses of gel significantly improved sexual performance, motivation, and desire, as well as spontaneous erections. The patch provided improvements from baseline at all sample times for sexual performance, motivation, and desire, but no statistically significant effect on spontaneous erections. Gel treatment was well tolerated, while patch treatment produced higher rates of application site reactions, resulting in greater study discontinuation.

Hypogonadal male subjects (n=406) reporting 1 or more symptoms of low testosterone were randomized in a double-blinded manner to testosterone 1% gel (50 and 100 mg/day) or placebo, and an open-label manner to testosterone patch (two 2.5 mg patches, old formulation). Subjects on the testosterone gel could be titrated up or down at day 60 on the basis of their day 30 serum testosterone level. Primary end points evaluated at 30 and 90 days included significant changes in the frequency of intercourse, nighttime erections, and sexual desire measured on a Likert-type scale and calculated as a mean daily score. At day 30, a significant increase from baseline in sexual desire score was noted for those on 100 mg/day gel compared with those on 50 mg/day gel, patch, or placebo (1.2 versus 0.4, 0.7, and 0.4, respectively; p<0.0013). A significant increase from baseline in the frequency of nighttime erections was also noted for those on 100 mg/day gel compared with those on 50 mg/day gel or placebo (51 versus 30, 26%, respectively; p<0.003), as well as for the patch versus placebo (p=0.0278). Finally, a significant increase from baseline in the frequency of intercourse was evidenced for those on 100 mg/day gel compared with those on patch or placebo. Similar results were seen for 100 mg/d testosterone gel at day 90 for sexual desire and nighttime erections versus placebo.

In a 90-day open-label study, pharmacokinetics and treatment effectiveness of testosterone 1% gel were compared at 50 and 100 mg/day to a testosterone patch (two 2.5 mg patches, old formulation) and placebo gel in 406 hypogonadal men. Pharmacokinetic profiles were obtained, body composition was measured, and mood and sexual function were monitored. Gel treatments resulted in dose-dependent improvements in all pharmacokinetic parameters compared with the testosterone patch and placebo. Mean average concentrations at day 90 were 13.8, 17.1, 11.9, and 7.3 nmol/L for 50 mg/day gel, 100 mg/day gel, patch, and placebo, respectively. At day 90, the 100 mg/day treatment improved lean body mass by 1.7 kg and percentage of body fat by 1.2%; this was significantly greater than either patch or placebo (p<0.05). Significant improvements in spontaneous erections, sexual desire, and sexual motivation were also evidenced with the 100 mg/day dose in comparison with placebo; the patch also had significant increases with the exception of spontaneous erections. No differences in positive or negative mood were seen between groups. The testosterone patch resulted in a high rate of application site reactions.
SUMMARY

Based on available data, there are no apparent differences in efficacy among the various products within this class as all medications produce increased levels of circulating testosterone, and all carry the same indication.

The gel and solution formulations of testosterone, however, do demonstrate a lower incidence of adverse reactions related to administration compared to the patches. The nasal gel also has a lower incidence of administration related adverse reactions. However it does have a greater number of nasal adverse effects and should not be used in patients with chronic nasal conditions. Long-term studies that evaluate topical treatment options for hypogonadism are lacking. The 2010 Endocrine Society testosterone therapy guideline recommends selecting a testosterone regimen on the basis of the patient’s preference, pharmacokinetics profile, treatment burden, and cost.

Vogelxo is the most recent topical gel entry in this class, while Androgel 1.62% is a newer strength available along with Androgel 1%. While they share the same active ingredient, Androgel 1% and Androgel 1.62% have separate prescribing information. Androderm transdermal testosterone has been reconfigured by the manufacturer to a transdermal system with a 20% lower dose of testosterone in a smaller patch that the previous formulation. The 2.5 mg/day and 5 mg/day patches have been replaced by 2 mg/day and 4 mg/day transdermal patches which are still intended for once daily use. Natesto offers a nasal gel formulation as an alternative to topical gels or solutions and testosterone patches.

All testosterone products are Schedule III controlled substances.

REFERENCES

1 Androgel [package insert]. North Chicago, IL; AbbVie; October 2016.
2 Androgel 1.62 [package insert]. North Chicago, IL; AbbVie; October 2016.
3 Fortesta [package insert]. Malvern, PA; Endo; October 2016.
4 Testim [package insert]. Malvern, PA; Auxilium; October 2016.
5 Vogelxo [package insert]. Maple Grove, MN; Upsher-Smith; October 2016.
7 Axiron [package insert]. Indianapolis, IN; Lilly; February 2017.
13 Androgel [package insert]. North Chicago, IL; AbbVie; October 2016.
14 Androgel 1.62 [package insert]. North Chicago, IL; AbbVie; October 2016.
15 Fortesta [package insert]. Malvern, PA; Endo; October 2016.
16 Testim [package insert]. Malvern, PA; Auxilium; October 2016.
17 Axiron [package insert]. Indianapolis, IN; Lilly; February 2017.
21 Androgel [package insert]. North Chicago, IL; AbbVie; October 2016.
22 Androgel 1.62 [package insert]. North Chicago, IL; AbbVie; October 2016.
23 Fortesta [package insert]. Malvern, PA; Endo; October 2016.
25 Axiron [package insert]. Indianapolis, IN; Lilly; February 2017.


